Who Generates Higher Gross Profit? Gilead Sciences, Inc. or Grifols, S.A.

Gilead vs. Grifols: A Decade of Profit Trends

__timestampGilead Sciences, Inc.Grifols, S.A.
Wednesday, January 1, 2014211020000001699214000
Thursday, January 1, 2015286330000001930998000
Friday, January 1, 2016261290000001912291000
Sunday, January 1, 2017217360000002152011000
Monday, January 1, 2018172740000002049560000
Tuesday, January 1, 2019177740000002341232000
Wednesday, January 1, 2020201170000002255165000
Friday, January 1, 2021207040000001962596000
Saturday, January 1, 2022216240000002231530000
Sunday, January 1, 2023206180000002322701000
Monday, January 1, 202478200000
Loading chart...

Infusing magic into the data realm

Gilead Sciences vs. Grifols: A Decade of Gross Profit

In the competitive landscape of the pharmaceutical industry, Gilead Sciences, Inc. and Grifols, S.A. have been key players. Over the past decade, Gilead Sciences has consistently outperformed Grifols in terms of gross profit. From 2014 to 2023, Gilead's gross profit peaked in 2015, reaching nearly 30% higher than its average over the period. In contrast, Grifols showed a steady increase, with its highest gross profit in 2019, marking a 38% rise from its 2014 figures.

While Gilead's profits have fluctuated, Grifols has demonstrated a more stable growth trajectory. This trend highlights Gilead's dominance in the market, yet also underscores Grifols' resilience and potential for future growth. As the pharmaceutical industry evolves, these financial insights provide a glimpse into the strategic maneuvers of these two giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025